2. Academic Validation
  3. VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia

VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia

  • J Med Chem. 2012 Jan 26;55(2):725-34. doi: 10.1021/jm201198w.
David K Heidary 1,  George Huang,  Diane Boucher,  Jianguo Ma,  Cornelia Forster,  Ron Grey,  Jinwang Xu,  Michael Arnost,  Deborah Choquette,  Guanjing Chen,  Jie-Hua Zhou,  Yung-Mae Yao,  Edward D Ball,  Mark Namchuk,  Robert J Davies,  Greg Henkel
Affiliations

Affiliation

  • 1 University of Kentucky, Department of Chemistry, Lexington Kentucky 40506, United States.
PMID: 22221201 DOI: 10.1021/jm201198w
Abstract

In acute myelogenous leukemia (AML), the FLT3 receptor tyrosine kinase (RTK) is highly expressed with 30% of patients expressing a mutated, constitutively active form of this protein. To inhibit this receptor, VX-322 was developed and found to be very potent against both the FLT3 and c-Kit RTKs with Enzyme K(i) values of <1 nM and a cellular IC(50) between 1 and 5 nM. It was efficacious in a FLT3-ITD dependent myeloproliferative mouse model, doubling survival compared to Other FLT3 inhibitors, with 25% of the mice cured. Upon treatment of primary AML patient blast cells, the dual inhibition of FLT3 and c-Kit was superior to inhibitors targeting a single RTK. Thus, this compound may represent an improved pharmacologic and selectivity profile that could be effective in the treatment of AML.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z